Compared to cell lines, primary cell culture is more able to reflect the physiological state of cells in the body. Therefore, primary cells have become an ideal tool for in vitro research with regards to diseases and mechanisms. They have been highly valued by researchers.
Under normal in vitro culture conditions, primary cells derived from normal/tumor tissues can grow and divide, but after 2 or 3 passages, the proliferation will stop, and aging and death occurs. This limits the studies on cells. Therefore, in the absence of viral or cell oncogene non-genetic manipulation, without changing any of the genetic or phenotypes of the cell, the cell culture technique that promotes normal growth and continuous passage of primary tumor cells in vitro is of great significance and application prospects.
Creative Bioarray, an innovative biotechnology company, can separate, culture, proliferate and continuously pass primary tumor cells derived from human and animal sources through by its cutting-edge isolation and culture techniques, and construct a fully functional tumor cell bank. The cell bank provides an ideal cell model for in vitro studies.
Personalized precision treatment - anti-tumor drug sensitivity test
Many cancer patients have problems with being insensitive to chemotherapeutic drugs or gradually becoming resistant to drugs during chemotherapy, leading to tumor recurrence or death. In addition, the patient's resistance to drugs is difficult to predict before chemotherapy, and chemotherapy failure and continuous attempts of various chemotherapy regimens will result in physical damage, economic waste, and loss of treatment opportunities to patients.
In vitro drug sensitivity testing is used to detect the cell viability of anti-tumor drugs, and select the most effective chemotherapeutic drugs or combinations, which becomes an important basis for personalized treatment. By this procedure, the probability of adverse reactions in patients will be significantly reduced. It is worth mentioning that some drugs originally appear to be ineffective for most patients, the strategy of individualized medication can help them find a suitable group of people, to reduce patient's illness, and avoid blind test.
At present, the problems in the construction of drug sensitivity testing model include: long cycle, low success rate, high cost, complex stromal tumor cells, difficulty in subculture, and no matching model of normal and tumor of the same individual.
Creative Bioarray, an innovative biotechnology company, can use the self-developed technology to isolate and culture the normal biopsy samples during a short time, and rapidly proliferate normal and tumor-matched primary cells from the same individual. By this, the original characteristics of the tumor cells are maintained, and the primary cells are also continuously passed for repeated use by the same donor.
Anticancer drug efficacy test
At present, many anticancer drugs have shown good anti-tumor activity in preclinical studies, but in clinical Phase I or Phase II trials, there are problems of high failure rate or unsatisfactory clinical application. The important reason is the lack of a model that accurately reflects the biological characteristics of a patient's tumor for testing and predicting antitumor activity. It has been found that the biological characteristics and genetic background of cell lines and patient tumors have undergone major changes. In addition, the problem of tumor heterogeneity has gradually been recognized, cell lines can not represent the heterogeneity and diversity of the tumor, so the pre-clinical test results are obvious, but the actual clinical trials are less effective. Therefore, it is of great significance and application value to establish a cell model of a tumor patient that is close to the biological characteristics of the patient's tumor. It can reflect the real situation of the patient and save the research and development cost for the enterprise.
Creative Bioarray, an innovative biotechnology company, can use its isolation and culture technology to isolate, culture, and pass through patient’s primary tumor cells. By in vitro isolation and culture of primary tumor cells from drug-resistant patients, a cell model for testing the effectiveness of new anticancer drugs was developed.
Safety evaluation of new anticancer drugs
About 30% of the failures in new drug development are due to safety issues, so it is important to conduct a comprehensive safety assessment in the development of new drugs. According to statistics, it takes about 10 years for a new anti-cancer drug to go from research and development to market listing, costing about 1 billion US dollars, of which 2/3 of the money is spent on inappropriate toxicity evaluation.
In general, in vivo screening can better evaluate the relevant properties of drugs, but because of its long cycle, high cost, low efficiency, etc., it is difficult to adapt to large-scale screening requirements, plus in considerations of animal welfare., it is imperative to seek and use faster and more effective alternatives to toxicity testing.
Creative Bioarray, an innovative biotechnology company, can use its own technology to construct animal models for safety evaluation.
Further reading: Tumor Cell Culture Guide